1-9 of 9
Vallari Shah
Close
Sort by
Journal Articles

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Matthew Jenner, MBBS, MRCP, FRCPath, Amy L Sherborne, PhD, Andrew Hall, Vallari Shah, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, James Croft, MBBS, BSc, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Louise Flanagan, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Ruth M De Tute, BSc,MSc, Roger G. Owen, MD, Guy Pratt, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser
Journal: Blood
Blood (2019) 134 (Supplement_1): 3162.
https://doi.org/10.1182/blood-2019-123547
Published: 2019
Journal Articles

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Clinical Trials & Observations Brief Report
Vallari Shah, David C. Johnson, Amy L. Sherborne, Sidra Ellis, Frances M. Aldridge, Julie Howard-Reeves, Farzana Begum, Amy Price, Jack Kendall, Laura Chiecchio, Suvi Savola, Matthew W. Jenner, Mark T. Drayson, Roger G. Owen, Walter M. Gregory, Gareth J. Morgan, Faith E. Davies, Richard S. Houlston, Gordon Cook, David A. Cairns, Graham Jackson, Martin F. Kaiser
Journal: Blood
Blood (2018) 132 (23): 2465–2469.
https://doi.org/10.1182/blood-2018-06-857250
Published: 2018
Includes: Supplemental data
Journal Articles

Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS- mutant Multiple Myeloma

Priya Sriskandarajah, MBBS, BSc, MRCP, Kevin Boyd, Wen Xu, MD, Irene Moreno Candilejo, MD, Sidra Ellis, Amy Price, Amy L Sherborne, PhD, James Croft, MBBS, BSc, Vallari Shah, MBBS, Joanna Dawes, PhD, Mona Parmar, Alison Turner, Emma Hall, BSc, MSc, PhD, Nina Tunariu, MBBS, MDes, MRCP, FRCR, Juanita S Lopez, MB BChir, MRCP, PhD, Johann S. de Bono, Udai Banerji, MBBS, MD DNB, PhD FRCP, Martin Kaiser, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3237.
https://doi.org/10.1182/blood-2018-99-111821
Published: 2018
Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Vallari Shah, MBBS, David C. Johnson, PhD, Amy L Sherborne, PhD, Sidra Ellis, Amy Price, Jack Kendall, Laura Chiecchio, PhD, Alina Striha, Anna Hockaday, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Matthew Jenner, Mark T Drayson, Roger G Owen, MD, Walter M Gregory, Gareth Morgan, MD, Faith E. Davies, MD, Richard S Houlston, MD PhD, Gordon Cook, David Cairns, Graham H Jackson, Martin Kaiser, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2000.
https://doi.org/10.1182/blood-2018-99-110149
Published: 2018
Journal Articles

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

Vallari Shah, MBBS, Amy L Sherborne, PhD, Sidra Ellis, David C. Johnson, PhD, Farzana Begum, Jack Kendall, Brian A Walker, PhD, John R Jones, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Suvi Savola, Matthew W Jenner, Mark T Drayson, MD PhD, Roger G. Owen, MD, David Cairns, BSc, MSc, PhD, Walter M Gregory, PhD, Richard S Houlston, MD PhD, Faith E Davies, MD, Gordon Cook, MD PhD FRCP, FRCPath, Gareth J. Morgan, MD PhD, Graham Jackson, MDPhD, Martin F Kaiser, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4331.
https://doi.org/10.1182/blood.V130.Suppl_1.4331.4331
Published: 2017
Journal Articles

Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Martin F Kaiser, MD, David Cairns, BSc, MSc, PhD, Alina Striha, MSc, John R Jones, MD, Vallari Shah, MBBS, Matthew W Jenner, Mark T Drayson, MD PhD, Roger G Owen, MD, Walter M Gregory, PhD, Gordon Cook, MD PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Faith E Davies, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3040.
https://doi.org/10.1182/blood.V130.Suppl_1.3040.3040
Published: 2017
Journal Articles

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Andrew Hall, Katrina Walker, Sidra Ellis, Farzana Begum, David C Johnson, James Croft, BSc, MBBS, MRCP, Jack Kendall, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Lilit Atanesyan, Suvi Savola, Louise Flanagan, Anjan Thakurta, PhD, Mamta Garg, MD, Gordon Cook, MD PhD, Kevin Boyd, Sarah Brown, Martin F Kaiser, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1851.
https://doi.org/10.1182/blood.V130.Suppl_1.1851.1851
Published: 2017
Journal Articles

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Sidra Ellis, Farzana Begum, Jack Kendall, David C Johnson, Roger G Owen, MD, Mark T Drayson, MD PhD, Louise Flanagan, Debbie Sherratt, Walter M Gregory, PhD, Graham Jackson, MDPhD, Guy Pratt, MD FRCP, FRCPath, Gordon Cook, MD PhD, Samantha Hinsley, Sarah Brown, Matthew W Jenner, Martin F Kaiser, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1767.
https://doi.org/10.1182/blood.V130.Suppl_1.1767.1767
Published: 2017
Journal Articles

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Andrew T. Vaughan, Chisako Iriyama, Stephen A. Beers, Claude H. T. Chan, Sean H. Lim, Emily L. Williams, Vallari Shah, Ali Roghanian, Bjorn Frendéus, Martin J. Glennie, Mark S. Cragg
Journal: Blood
Blood (2014) 123 (5): 669–677.
https://doi.org/10.1182/blood-2013-04-490821
Published: 2014
Includes: Supplemental data